Gilead Sciences ((GILD)), Gilead Sciences (($CC:GILD.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Gilead Sciences is conducting a Phase 3 clinical study titled A Phase 3, Randomized, Open-Label, Active-Controlled Study to Evaluate a Switch to an Oral Weekly Islatravir/Lenacapavir Regimen in People With HIV-1 Who Are Virologically Suppressed on Standard of Care. The study aims to assess the safety and efficacy of switching to a once-weekly oral regimen of islatravir/lenacapavir (ISL/LEN) compared to continuing the standard of care in virologically suppressed individuals with HIV-1.
The intervention being tested is the ISL/LEN regimen, which is a weekly oral tablet designed to maintain viral suppression in HIV-1 patients. The standard of care involves 2 or 3 antiretroviral agents.
The study follows an interventional design with randomized allocation and a parallel intervention model. It is open-label, meaning no masking is involved, and its primary purpose is treatment.
The study started on October 8, 2024, with the primary completion date set for 48 weeks after the start. The last update was submitted on July 9, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
This clinical update could influence Gilead Sciences’ stock performance by potentially enhancing investor confidence if the results demonstrate significant benefits of the ISL/LEN regimen. The study’s outcome may also impact the competitive landscape in HIV treatment, where Gilead is a key player.
The study is ongoing, with further details available on the ClinicalTrials portal.